Completed
Vigorous exercise and HCM: LIVE-HCM Trial
Class Central Classrooms beta
YouTube videos curated by Class Central.
Classroom Contents
Current and Evolving Understanding in Hypertrophic Cardiomyopathy - Cardiology Grand Rounds
Automatically move to the next video in the Classroom when playback concludes
- 1 Current and Evolving Understanding in Hypertrophic Cardiomyopa
- 2 Hypertrophic Cardiomyopathy: Some simple math
- 3 Step 1: Multimodality imaging key in diagnosing HCM
- 4 Recognition of Apical aneurysms
- 5 LV Strain
- 6 NIH Sponsored HCMR Registry
- 7 Machine learning. LV shape and insights into pathophysiology
- 8 AI, EKG, HCM
- 9 Machine learning and HCM
- 10 Elicit LVOT Obstruction: Don't look, Won't find, Can't Tre
- 11 Stress Echo
- 12 Recognize typical and atypical variants of obstructive HC OCM without the H: Abnormal mitral subvalvular morphology
- 13 3 different flavors of "Atypical" LVOT obstruction
- 14 Differential diagnosis using multimodality imaging
- 15 Important to make the correct diagnosis
- 16 SCD risk stratification
- 17 Comparison of ESC vs. American Approach
- 18 ICD placement
- 19 HCM LGE Outcomes
- 20 Screening Echo vs. CMR in G+P-patients
- 21 Management in oHCM
- 22 Lifestyle considerations
- 23 Vigorous exercise and HCM: LIVE-HCM Trial
- 24 In oHCM, there are no prospective RCT (single or multicenter) compar a various FDA-approved medical therapies b invasive therapies vs. FDA-approved medical Rx c myectomy vs. alcohol ablation
- 25 Septal Reduction Therapy: One operation does not fit
- 26 Cleveland Clinic approach to Surgical LVOT obstructi
- 27 Alcohol septal ablation
- 28 Guidelines: Invasive therapies
- 29 Spectrum of oHCM management in USA
- 30 Expert Centers Have Markedly Better SRT Outcomes But Access to Specialty Centers Are Limited
- 31 Mavacamten Prevents Disease Phenotype in HCM Mice
- 32 Phase III RCTs: Testing Mavacamten vs. Placebo EXPLORER-HCM vs. VALOR-HCM
- 33 Mavacamten LTE study
- 34 Valor-HCM: 92% NYHA Class III 19 US HCM Centers
- 35 Primary endpoint and NYHA Class Improvement
- 36 Secondary Efficacy Endpoints
- 37 Favorable Cardiac Remodeling
- 38 A VALOR Mavacamten Story
- 39 LVEF and mavacamten: Implications in clinical practice
- 40 Clinical management of Camzyos (Mavacamten)
- 41 Gene-therapy: Adeno-associated Virus mediated
- 42 These new therapies are going to bring new logistic scenarios, assum long-term safety and efficacy
- 43 Symptomatic Nonobstructive HCM
- 44 Managing Arrhythmias Atrial fibrillation: A Bad Actor in HCM, especially oHCM
- 45 Management of AF
- 46 Genetic Testing in HCM
- 47 Genetics and long-term outcomes: SHARE registry!
- 48 Screening of asymptomatic first-degree relativ EKG and echo
- 49 Valsartan in Early Stage HCM: VANISH Trial
